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Abstract
Modeling of retrospectively collected multi-center data of a rare disease in pediatrics is challenging because laboratory
data can stem from several decades measured with different assays. Here we present a retrospective pharmacometrics
(PMX) based data analysis of the rare disease congenital hypothyroidism (CH) in newborns and infants. Our overall aim is
to develop a model that can be applied to optimize dosing in this pediatric patient population since suboptimal treatment of
CH during the first 2 years of life is associated with a reduced intelligence quotient between 10 and 14 years. The first goal
is to describe a retrospectively collected dataset consisting of 61 newborns and infants with CH up to 2 years of age.
Overall, 505 measurements of free thyroxine (FT4) and 510 measurements of thyrotropin or thyroid-stimulating hormone
were available from patients receiving substitution treatment with levothyroxine (LT4). The second goal is to introduce a
scale/location-scale normalization method to merge available FT4 measurements since 34 different postnatal age- and
assay-specific laboratory reference ranges were applied. This method takes into account the change of the distribution of
FT4 values over time, i.e. a transformation from right-skewed towards normality during LT4 treatment. The third goal is to
develop a practical and useful PMX model for LT4 treatment to characterize FT4 measurements, which is applicable
within a clinical setting. In summary, a time-dependent normalization method and a practical PMX model are presented.
Since there is no on-going or planned development of new pharmacological approaches for CH, PMX based modeling and
simulation can be leveraged to personalize dosing with the goal to enhance longer-term neurological outcome in children
with the rare disease CH.
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Introduction
Analysis and modeling of retrospective clinical data are
important to characterize a patient cohort under treatment
and to model general and individual disease progression to
quantitatively describe unsolved clinical problems, e.g. in a
dose- or disease severity-dependent way. Especially for
rare diseases, defined as condition that affects less than 200
000 people in the US [1] or less than 1 out of 2000 people
in the European Union [2], retrospective data analysis of
patients diagnosed during a time window of 10 to 20 years
is crucial for overcoming the limitation of the low number
of patients in the general population. Rigorous retrospec-
tive analyses pave the way to successful planning of
prospective studies. For rare diseases, there is often no on-
going or planned development of new pharmacological
approaches. Hence, personalized dosing based on phar-
macometric (PMX) modeling and simulation [3, 4] is the
next logical step to enhance medical treatment in patients
with a rare disease. However, before general application of
such PMX models, their accuracy needs to be validated in
prospective controlled studies.
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PMX modeling of retrospectively collected data of a
rare disease originating from several decades and different
centers is challenging. First, measurements of one specific
laboratory parameter were performed with different com-
mercially available laboratory assays at different centers.
Second, different generations of the same laboratory assay
over time in the same center are associated with varying
reference ranges. Third, a majority of guidelines for stan-
dardized clinical and laboratory follow-up for a specific
rare disease were developed during the last 5 to 10 years,
which may result in specific clinical and laboratory
investigations varying from center to center especially in
older datasets.
Here we present retrospective data analysis and mod-
eling of congenital hypothyroidism (CH) which is a rare
disease (ORPHA:442) that affects 1 out of approximately
1500 to 4000 newborns [5, 6]. In patients with primary or
thyroidal CH, the thyroid gland does not produce sufficient
thyroid hormones leading untreated to growth failure and
strongly reduced neurological outcome. Therefore, the
manufactured form levothyroxine (LT4) of the thyroid
hormone thyroxine (T4) is applied to treat thyroid hormone
deficiency. CH is the most frequent preventable cause of
mental retardation worldwide. Neurological outcome of
CH patients has been strongly improved in the last 40 years
by introducing systematic neonatal screening for preclini-
cal diagnosis in the 1970s [7, 8], and by increasing the
starting dose of LT4 at diagnosis from 5–10 to 10–15 mcg/
kg body weight in the 1990s [9, 10]. The main aim was to
aggressively correct laboratory hypothyroidism as rapidly
as possible to protect thyroid-hormone dependent neu-
rodevelopment in the newborn affected by CH, as during
pregnancy, hypothyroidism of fetuses affected by CH is
only partially compensated by transplacental passage of
maternal thyroid hormones [11]. Recent data however
revealed frequent long-lasting overdosing of patients under
the recommended initial dose of 10–15 mcg/kg body
weight [12, 13]. Finally, different studies showed a nega-
tive effect of long-term elevated plasma thyroxine levels
during the first years of life on the intelligence quotient
between 10 and 14 years [14–16]. Therefore, it is essential
to develop a mathematical PMX model to characterize
individual dynamics of substituted thyroxine and to further
optimize and personalize LT4 treatment in the context of
rapid weight gain during infancy and three disease severity
levels (mild, moderate and severe CH disease according to
current guidelines) [5].
This article has three goals. First, a retrospectively
collected dataset consisting of n = 61 newborns and infants
with CH up to 2 years of age is described. Second, due to
the multi-center/-assay nature of the data, a scale/location-
scale normalization method is developed to make the
measured free T4 (FT4) concentrations comparable by
normalization to a target reference range. For normaliza-
tion, it is essential that underlying statistical assumptions of
the methods are fulfilled in the dataset. Since FT4 mea-
surements change their distribution during treatment,
namely from a right-skewed distribution (scale formula)
towards normality (location-scale formula), this time-de-
pendent transition of the distribution is taken into account
in the developed normalization method. Third, a mathe-
matical model to characterize FT4 measurements and LT4
treatment has to be in a fair balance between the physio-
logical mechanism and the capability to characterize
available data. The hypothalamic-pituitary-thyroid (HPT)
axis is a complex multi-loop feedback mechanism where,
among many others, T4 and thyroid-stimulating hormone
(TSH) control themselves to hold all thyroid hormones in a
healthy equilibrium. Interestingly, mathematical modeling
of the HPT axis has a long history ranging back to the
1950s [17, 18]. However, most mathematical models
developed in the last decades are pretty detailed [19–21],
based on animal data [22], or focus on a very specific
question such as the relationship between TSH and FT4
[23, 24]. Application of such models to data collected in
daily clinical routine from CH patients is usually impos-
sible because many model parameters are not identifiable
due to lack of large quantitative data. Therefore, we
developed a practical PMX model describing FT4 con-
centration and LT4 treatment.
In summary, a PMX model for FT4 concentration and
LT4 treatment based on normalized FT4 measurements is
presented. The normalization method takes the transition
from a right-skewed distribution towards normality during
LT4 treatment into account. Such a PMX model can be
applied to characterize FT4 under LT4 substitution therapy
with the goal to further personalize and enhance LT4
treatment in pediatric patients with a rare disease.
Methods
The Method section consists of six paragraphs. First, study
design and retrospective data collection procedure to form
the pediatric CH study population based on data from four
different hospitals over the last 25 years are reported.
Second, a descriptive analysis of the collected data is
presented. Third, normalization procedures for laboratory
reference ranges stemming from different assays are
introduced. Fourth, a PMX model to characterize FT4
concentration based on remaining endogenous T4 produc-
tion and exogenous LT4 administration is presented. Fifth,
available covariates are discussed and finally, some
remarks about applied statistics and software are presented.
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Study design
A retrospective multi-center longitudinal cohort study of
consecutive pediatric patients diagnosed with primary or
thyroidal CH based on elevated TSH values in neonatal
screening and confirmatory laboratory testing was per-
formed between 01/1990 and 08/2018 in Switzerland. Data
from neonates and infants up to approximately 2 years of
age were included if they (i) had a confirmed diagnosis of
primary or thyroidal CH, (ii) were treated at the partici-
pating study centers (a) between 01/1990 to 08/2018
(University Children’s Hospital Basel, University Hospital
Bern, University Children’s Hospital Zurich) or (b) be-
tween 01/1990 to 12/2013 (Children’s Hospital Eastern
Switzerland, St. Gallen), (iii) had a complete dataset,
including (a) clinical baseline characteristics, (b) labora-
tory parameters at diagnosis and/or LT4 treatment start,
and (c) LT4 dose history during the complete follow-up,
(iv) had C 2 follow-up visits after LT4 treatment start.
Patients were excluded, (i) if LT4 start dose and LT4 doses
during follow-up visits were missing, (ii) in case of treat-
ment noncompliance, or (iii) in all cases of central
hypothyroidism. Data were captured standardized in the
designated electronic database secuTrial for each study
visit. An ethical approval for this study (2018-01770) was
obtained by the lead local Ethics Committee (Ethikkom-
mission Nordwest- und Zentralschweiz EKNZ) and all
local responsible Ethics Committees (Kantonale
Ethikkommission Bern, Ethikkommission Zürich,
Ethikkommission Ostschweiz EKOS). Data from patients
were used pseudonymized. The study was performed in
compliance with the Helsinki Declaration and Good Clin-
ical Practice.
Descriptive analysis of the retrospective data
In total, n = 71 pediatric patients with the rare disease CH
fulfilled all inclusion criteria. Clinical records are often
stored for approximately 20 years as the patients were
monitored from birth until transition to an adult endocri-
nologist and the retention requirement is 10 years in
Switzerland. In addition to the inclusion and exclusion
criteria formulated above, only patients with more than
2 months of treatment were included in this analysis.
Therefore, the final number of patients involved in the
analysis was n = 61 (female = 70%).
Laboratory data from start of LT4 treatment
ðt0 = 0 day) were included in the analysis. Measurements
of non-normalized FT4 (n = 505) and TSH (n = 510) are
shown in Fig. 1. On average, 8 FT4 measurements were
available per patient with minimally 4 and maximally 14
measurements. Disease severity was defined based on the
first FT4 measurement at time of diagnosis, i.e. 18 patients
were categorized as severe (FT4\ 5 pmol/l), 17 as mod-
erate (FT4 C 5 and\ 10 pmol/l) and 21 as mild (FT4
C 10 pmol/l) according to current guidelines [5]. Five
patients had no initial FT4 measurement. Patient charac-
teristics such as gestational age (GA) as well as postnatal
age (PNA), weight, non-normalized FT4 and TSH con-
centrations, and in addition, total daily LT4 dose and LT4
dose per kg body weight all at start of treatment and last
available follow-up with a FT4 measurement, are presented
in Table 1.
Normalization of FT4 concentrations with respect
to different laboratory reference ranges
Available laboratory reference ranges of the FT4
measurements and PNA dependent target reference ranges
Each of the measured FT4 values in our dataset is
accompanied by a corresponding laboratory reference
range. These ranges are PNA dependent but also assay- and
center-related. In total, 34 different FT4 laboratory refer-
ence ranges were identified for the 505 measurements.
Observed laboratory reference ranges from all FT4 mea-
surements over time are shown in Fig. 2. We observe that
during the first 30 days, few upper limits of the reference
ranges are unusually large.
To merge all FT4 measurements from the four clinical
centers, a normalization method was constructed based on
PNA dependent target reference ranges taken from Kape-
lari et al. [25], see Table 2 for the 2.5 and 97.5 percentiles
and Fig. 2. After normalization, the FT4 values can be
treated as if they were obtained from a single standard
laboratory [26].
Construction of a time-dependent normalization method
during treatment
A normalization method is based on statistical assumptions
which have to be verified prior to application. We observed
that the distribution of FT4 measurements changes during
treatment in our CH population. At time of diagnosis, non-
normalized FT4 measurements follow a right-skewed dis-
tribution with several values close to zero, representing the
disease severity in our cohort of severe, moderate and mild
forms (Fig. 3a). However, during treatment, the distribu-
tion transforms towards normality, as shown in Fig. 3b–d
for different time points and intervals. Since successfully
treated patients have FT4 values in the healthy range, such
a distribution is expected.
We denote with xmeas the performed FT4 measurement
and with rlow and rup the value of the lower and upper
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limits of the laboratory reference range associated with this
measurement. In addition, rStdlow and r
Std
up denote the lower
(2.5 percentile) and upper (97.5 percentile) limits of the
PNA dependent target reference range taken from Table 2.
Karvanen [26] proposed and derived for right-skewed
distributions a scale normalization formula to compute the
normalized FT4 value xnorm:




For normally distributed data, it was shown that the
Chuang-Stein formula [27], also called location-scale
normalization formula,






is valid. For more details and justification of Eqs. (1) and
(2) see [26].
Since the FT4 distribution transforms from right-skewed
to normal during treatment, we propose a combination of
the scale and location-scale formula. More precisely, for
small times t the scale formula is dominant. For increasing
times t up to a certain time threshold ts, the scale formula
transforms into a mixture of scale and location-scale for-
mula. After the threshold ts, only the location-scale formula
is applied:
Fig. 1 Non-normalized FT4 measurements (n = 505) are shown in panel a and b. TSH measurements (n = 510) are shown in panel c and d
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Table 1 Demographic and
laboratory patient
characteristics at start of LT4
treatment and at last available
follow-up
Unit Median [IQR] [Min, Max]
Patient parameters at start of treatment
GAa week 40.5 [38.0, 41.3] [28.3, 42.9]
PNA day 7 [6, 9] [3, 231]
Weightb kg 3.3 [2.9, 3.8] [0.95, 8.07]
FT4c pmol/l 7.0 [3.4, 12.3] [1.2, 20.4]
TSHd mU/l 267 [146, 430] [7.6, 1026]
LT4 dose total daily mcg/day 25 [25, 37.5] [10, 50]
LT4 dose per kg body weightf mcg/kg/day 8.8 [6.8, 13.02] [2.8, 28.4]
Patient parameters at last available follow-up with FT4 measurement
PNA day 602 [362, 708] [98, 769]
Weighte kg 11.3 [9.4, 12.7] [4.3, 15]
FT4 pmol/l 21.0 [18.4, 25.6] [3, 35.5]
TSH mU/l 2.2 [0.90, 4.7] [0.005, 100]
LT4 dose total daily mcg/day 50 [37.5, 50] [15, 75]
LT4 dose per kg body weightf mcg/kg/day 3.8 [3.4, 4.4] [1.8, 6.7]
a13 values missing; b8 measurements missing; c5 measurements missing; d6 measurements missing; e6
measurements missing; fcomputed based on imputed values for missing weight measurements
Fig. 2 Presentation of all available laboratory reference ranges of FT4
measurements over time. Grey circles denote the upper limit and grey
crosses the lower limit of each range. Black lines show the upper and
lower limits of the target reference range (compare Table 2), where
for simplicity in this Figure, individual PNA at start of treatment was
neglected. The first 50 days are shown in panel a, and the total time
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PMX model to characterize FT4 based
on remaining endogenous T4 production
and exogenous LT4 treatment
Part I: structural PMX model for exogenous LT4 treatment
Oral exogenous LT4 mcg/day administration is character-
ized with the input function Inðtj; dosej;FÞ, where tj is the
dosing time point, dosej the total daily LT4 dose mcg/day
and F the bioavailability. The dose was converted with
factor 1.29 to nmol/day (molecular weight of thyroxine
776.9 g/mol). The absorption compartment AB nmol reads
d
dt
AB ¼ In tj; dosej;F
 
 ka  AB ; AB 0ð Þ ¼ 0 ð4Þ
with absorption rate ka.
Part II: structural PMX model for endogenous T4 production
We apply a typical one-compartment pharmacokinetic
model with linear first-order elimination and further
assume that a remaining endogenous T4 production is








where AC characterizes the central compartment with the
amount of T4 nmol. Linear elimination is described with
the first-order elimination rate kel 1/day and the initial
Table 2 Percentiles (2.5, 50 and 97.5) of the target reference range for
FT4 and TSH concentrations of neonates and infants based on post-
natal age taken from [25]
FT4 (pmol/l) TSH (mU/l)
Percentile 2.5 50 97.5 2.5 50 97.5
Postnatal age
0–1 months 8.50 20.10 30.50 0.70 3.50 18.10
1–12 months 9.17 15.50 25.28 1.12 2.85 8.21
1–5 years 10.45 15.70 22.35 0.80 2.70 6.26
Fig. 3 Change of distribution of
the non-normalized FT4
measurements from a right-
skewed distribution towards a
normal distribution for
increasing time of treatment.
Panel a shows the distribution at
start of treatment t = 0 of all
available FT4 measurements,
panel b and c show the
distribution for later time
intervals, whereas panel
d shows the distribution based
on the individual last
measurement time point
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condition assumes that the endogenous T4 production is in
an equilibrium prior to treatment. This assumption might
not be fully correct at start of treatment since the neonate
may still slightly benefit from transplacental passage of
maternal hormones until birth. However, after stopping the
treatment the amount of T4 will always return to the
equilibrium kendo
kel
given in Eq. (5) which is consistent with
the assumption that the disease cannot be cured.
Part III: structural PMX model with body weight
development
The FT4 concentration is derived by transforming the T4
unit nmol to pmol and assuming that the FT4 concentration
corresponds to 0.03% of T4 [28]. Therefore, FT4 concen-
tration pmol/l reads




where V l is the volume of distribution depending on
current body weight kg WðtÞ:





where f V l is a multiplicative factor relating body weight
with volume of distribution, WRef is the median of body
weight of the underlying population, and bW the power
exponent. Obviously, if the treatment stops, FT4 concen-
tration will return to an equilibrium which depends on the
current body weight.
Interpolation of body weight and TSH over time
In total, n = 474 measurements of body weight W were
available. Daily values for body weight and TSH were
imputed by non-linear interpolation.
Covariate modeling
Categorical (not time-varying) covariates were imple-
mented and tested with the default setting from The
Monolix Suite 2020R1 (Lixoft, Orsay, France). Continuous
covariates were tested at model parameters with the power
model




where hi is the individual model parameter, hpop is the
population model parameter (typical value), Covi is the
individual (possibly time-varying) covariate, CovRef is the
reference covariate value and b is the exponent describing
the covariate effect.
Covariate selection and testing
Covariates to be tested were selected based on complete-
ness, possible correlations among each other and clinical
plausibility.
GA was not available for all patients, however strongly
correlates with birth weight, and was therefore not tested.
PNA at start of treatment (continuous) and sex (categori-
cal) were included in covariate testing.
Body weight over time (time-varying) with the inter-
polated values for missing measurements was already
incorporated in the model to compute the volume of dis-
tribution, compare Eqs. (6) and (7). Body weight at start of
treatment (continuous) was not selected for testing because
8 measurements were missing and body weight over time
was already included.
TSH effects over time on the endogenous production rate
were testedwith twodifferent groupings. In thefirst group,TSH
values were categorized as follows: category 1 with TSH\3
mU/l (milliunits per liter) and category 2 with TSH C 3 mU/l.
The value 3 mU/l was selected since it corresponds to the
average of the median target reference range in our study
population, compare Table 2. In the second group, TSH values
were split into three categories: category 1 TSH\1 mU/l,
category 2 TSH C 1 and TSH\10 mU/l, and category 3
TSH C 10 mU/l. Chosen values roughly correspond to the
average of the lower and upper limits of the target reference
range, compare Table 2. Although it is obvious that a rela-
tionship between TSH at start of treatment (continuous) and
FT4at start of treatment exists,TSHat start of treatmentwasnot
selected because 6 measurements were missing.
Statistical data presentation and applied
software
All laboratory and demographic values are reported as
median together with the interquartile range (IQR) [25%,
75%]. Descriptive statistical analysis was performed in R
3.6.0 (R core team, Vienna, Austria) and hypothesis testing
was executed with the Student’s t-test for normally dis-
tributed values and with the Wilcox rank test for non-nor-
mally distributed values. Non-linearmixed-effectsmodeling
was performed in TheMonolix Suite 2020R1 (Lixoft, Orsay,
France). A-posteriori data visualization was implemented in
R or Matlab 2020a (MathWorks, Natick, MA, USA).
Results
The Results section consists of five paragraphs. First, the
non-normalized and normalized measurements are com-
pared. Second, model parameter estimates are presented.
Journal of Pharmacokinetics and Pharmacodynamics
123
Third, a TSH feedback effect on FT4 is tested. Fourth, the
final PMX model for CH is presented. Fifth, additional
tests are performed.
Comparison of non-normalized and normalized
measurements
Transition from a right-skewed towards a normal distri-
bution was expected at time threshold ts = 150 day,
compare Fig. 3. After application of the proposed scale/
location-scale formula Eq. (3), we observe that normalized
FT4 values are slightly but not significantly lower than
non-normalized measurements. Comparison for start of
treatment (t0 = 0), additional time intervals 0 \t\ 50,
100  t\ 150, and at t = last available time point are
presented in Table 3.
We emphasize that the application of the Chuang-Stein
(location-scale) formula alone resulted in 29 negative
values for FT4 at start of treatment. This was expected
since the normal assumption was violated (compare
Fig. 3a) and laboratory reference ranges were quite large
compared to the actual FT4 value.
TSH over time is a highly variable and sensitive marker
with absolute values ranging from the limit of quantifica-
tion up to 1026 mU/l in our study population, compare
Fig. 1b. An investigation of the distributions of TSH at
specific time points showed mostly right-skewed behavior
with no clear tendency towards normal (data not shown). In
total, 43 TSH measurements were not accompanied by
laboratory reference ranges (incomplete or missing) and
therefore, TSH was not normalized.
PMX model parameter estimation based
on normalized FT4 values
LT4 is variably absorbed and bioavailability is reported
between 40 to 80% (https://go.drugbank.com/drugs/
DB00451). We fixed the bioavailability to F = 0.6 in
Eq. (4). The model Eqs. (4)–(7) consists of the structural
model parameters ka, kendo, f V and kel. The absorption rate
ka was fixed to 20 1/day, realizing a maximal FT4 peak at
2 h [29], and had no inter-individual variability (IIV). The
endogenous production rate kendo, the factor f V relating
body weight with volume of distribution, as well as the
power exponent bW were estimated with a log-normal
distribution. Based on available data, the elimination rate
kel is difficult to estimate. Since T4 half-life in plasma is on
average 7 days [29], kel was fixed to 0.1 1/day. Allowing
IIV for kel resulted in a high shrinkage based on the indi-
vidual conditional mode estimations and a small standard
deviation of the random effects. Hence, IIV on this
parameter was omitted. We remark that a formulation of
the model in terms of clearance with a weight-based allo-
metric scaling approach was omitted because of (i) insuf-
ficient FT4 data to reasonably apply such an approach, (ii)
the lack of information regarding maturation effect on the
half-life in literature, and (iii) the rather small weight
range. Data fitting was performed with a proportional
residual error model.
PNA at start of treatment showed a significant but weak
effect on the endogenous production rate kendo. However,
the PNA effect was exclusively driven by 4 patients with
PNAs larger than 50 days. Without these 4 patients, no
significant effect was available. Therefore, the PNA effect
was not included in the final model. Sex had no effect on
any model parameter.
Test for TSH feedback effects on FT4
Low FT4 (or T4) values cause increased TSH levels which
in turn will try to stimulate the FT4 (or T4) production.
Therefore, we tested a TSH feedback on the endogenous
T4 production rate kendo. More precisely, kendo is modeled
as a function of TSH and changes over time, denoted by
kendo;Cov. Hence, kendo is now substituted by kendo;Cov in
Eq. (5). First, the previously defined two time-varying
categorical TSH groups were tested. For the first grouping
we applied
kendo;Cov ¼
kendo for category 1
kendo þ b1 for category 2

and for the second grouping:
Table 3 Comparison of non-normalized and normalized FT4 values for different time points and time intervals
Time points/intervals (day) Non-normalized FT4 (pmol/l) Median [IQR] Normalized FT4 (pmol/l) Median [IQR] Significance
Start of treatment (t0 = 0) 7.0 [3.4, 12.3] 5.2 [2.4, 10.4] N.s.
a
0 \t\ 50 33.6 [26.3, 45.2] 31.7 [22.6, 43.2] N.s.a
100  t\ 150 23.4 [19.5, 26.3] 20.6 [18.0, 24.1] N.s.a
Last available time point 21.0 [18.4, 25.6] 18.0 [16.0, 22.7] N.s.a
aNot significant
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kendo;Cov ¼
kendo for category 1
kendo þ b1 for category 2








Second, the effect of actual TSH measurements on kendo
were tested with
kendo;Cov ¼ kendo  f TSHð Þ
and
kendo;Cov ¼ kendo þ b3  f TSHð Þ
The function f TSHð Þ was either (i) f TSHð Þ ¼ TSH, (ii)
f TSHð Þ ¼ TSH
TSHRef
 b
, (iii) f TSHð Þ ¼ log TSHð Þ, or (iv)




Based on the available data, it was difficult to observe an
improvement in data fitting by including a TSH feedback
on the endogenous production rate. With a combined
assessment of typical data fitting criteria such as goodness-
of-fit plots, reduction of the objective function, reduction of
variability in random effects, and changes in standard error,
no overall improvement could be concluded. Therefore,
TSH feedback effect was not included in the model.
Final PMX model for CH based on normalized FT4
values
The final model consists of Eqs. (4)–(7) without any
additional covariate effects. Final model parameter esti-
mates are shown in Table 4. Visual predictive check is
presented in Fig. 4. Other goodness-of-fit plots and indi-
vidual profiles are available in the supplemental material.
Additional tests
In the following, an additional test was performed to fur-
ther verify the final PMX model Eqs. (4)-(7).
Comparison of results with parameter estimates from non-
normalized data
With the final model Eqs. (4)–(7), the non-normalized FT4
data were fitted and individual parameter values were
compared. The estimated individual parameter values for
the endogenous production rate kendo for non-normalized
FT4 values were significantly higher (p\ 0.005) than for
normalized values. Comparison of estimated individual
Table 4 Population estimates
(typical values), standard
deviation of the random effects
and additional parameters
obtained from fitting normalized
FT4 data with the final PMX
model Eqs. (4)–(7)
Parameter name Description Unit Estimate (r.s.e.a)
Population estimates (fixed effects)
ka Absorption rate 1/day 20 fix
kel Elimination rate 1/day 0.1 fix
f V Multiplicative factor l 4.96 (3.7)
bW Power exponent – 0.753 (6.6)
kendo Endogenous production rate nmol/day 3.66 (15.7)
Standard deviation of the random effects
xf V 0.249 (11.9)
xbW 0.404 (15.8)
xkendo 1.12 (11.1)
Additional parameters and values
Prop. residual error 0.228 (4.2)
- 2LL value 3268
aRelative standard error
Fig. 4 Visual predictive check based on normalized FT4 measure-
ments modeled with Eqs. (4)–(7)
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parameter values for f V and bW is more complicated since
the volume of distribution depends on both parameters as
given in Eq. (7). Hence, for any individual we have to
consider the pair ðf V ;bWÞ and compare the resulting vol-
ume of distribution obtained from non-normalized FT4
values to the resulting volume of distribution obtained from
normalized FT4 values. We restrict the comparison to the
volume of distribution at baseline and the volume of dis-
tribution for median body weight. In both situations, we
observe that the volume of distribution for non-normalized
FT4 values is significantly lower (p\ 0.005) than for
normalized data. Hence, these comparisons coincide with
the fact that normalized FT4 data were on average lower
than non-normalized FT4 data, compare Table 3.
Discussion
In this section we discuss the key findings in the context of
the three main goals of this research project: (i) Presenta-
tion of challenges associated with a retrospectively col-
lected dataset including long-term follow-up of 61
newborns and infants with a rare disease (CH). (ii)
Derivation of a time-dependent scale / location-scale nor-
malization method to account for the multi-center/-assay
nature of the data. (iii) Development of a practical PMX
model describing FT4 concentration and LT4 treatment.
The first goal of this article was to describe retrospec-
tively collected multi-center data from newborns and
infants with CH up to 2 years. Clinical and laboratory
records from children with a rare disease are stored for
approximately 20 years as such patients were followed
from birth until transition to an adult endocrinologist and
the retention requirement is 10 years in Switzerland. This
allowed for collecting data from patients ranging back to
1995 resulting in n = 61 newborns with CH after applica-
tion of inclusion and exclusion criteria. Assuming
approximately 80,000 live births per year in Switzerland in
the last decades (https://www.bfs.admin.ch) leads to the
total number of 1.8 million live births from 1995 to 2018.
The incident rate of CH in Switzerland is 1:3500 (https://
www.neoscreening.ch) resulting in approximately 515
newborns with CH between 1995 and 2018. Hence, our
dataset roughly consists of 12% of all newborns with CH in
Switzerland from 1995 to 2018. The dataset revealed the
major problem of strongly variable FT4 laboratory refer-
ence ranges especially in the first weeks of life. There are
several reasons for this. First, some reference ranges were
simply adult references not taking into account the higher
normative values in the neonates and young infants, while
other reference ranges were adapted to the neonatal and
infant age group. Second, during long-term observation,
laboratory assays and consequently reference ranges
changed for the same parameter within a center. Third,
different laboratory methods were used at different centers
and changed at different time points. Harmonization and
normalization of the clinical dataset was an important part
of the work before any modeling of the disease and the
therapy could have been done. While prospectively plan-
ned studies allow avoiding such technical hurdles, in rare
diseases with a limited number of patients at a single center
and even in a region or country, the retrospective approach
has the advantage to establish datasets for generating
hypotheses and modeling in parallel to the realization of a
prospective study. In summary, retrospective data analyses
are feasible even in the context of, as in our case, 34 dif-
ferent laboratory reference ranges, if normative data stan-
dardization is implemented.
The second goal was to develop a normalization
method. However, before developing such a method, we
have to discuss the well-known question of whether nor-
malization is indeed necessary. The answer depends on the
particular situation. On one hand, in drug development,
different reference ranges can usually be avoided by
applying standardized assays in the same laboratories right
from the beginning of the study. If this standardization is
not possible, it is suggested to ignore laboratory differences
and ‘‘the analyst must accept the data as is’’ [30] or con-
sider the application of normalization methods ‘‘as the last
resort’’ [31]. On the other hand, our multi-assay/-center
dependent nature of the measurements, as previously
explained, calls for a normalization method to reasonably
merge available data. The Chuang-Stein formula is a linear
approach to normalize data with different reference ranges.
Hence, normally distributed data will remain normally
distributed after application of the Chuang-Stein formula.
However, the Chuang-Stein formula can produce negative
normalized values in specific situations. This issue was
reported by Chuang-Stein [31] and was also observed when
applying the Chuang-Stein formula to our FT4 measure-
ments. Another issue is the assumption of normality itself
which is not fulfilled at start of treatment as shown for our
FT4 measurements. For such right-skewed distributed data,
Karvanen [26] derived a scale formula for normalization.
Therefore, we developed a time-dependent normalization
method that is based on the scale formula in the beginning
of treatment and transitions to the location-scale formula
for normally distributed data when the FT4 values are in
the healthy range.
The third goal was to develop a practical PMX model
for LT4 treatment to characterize FT4 measurements. The
major aim was that the PMX model can be applied in a
clinical setting. Therefore, the PMX model has to be in a
fair balance between the physiological mechanism and the
capability to be applied to routinely collected clinical data.
Already in the 1950s, Danziger et al. [18] published two
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systems of non-linear differential equations that describe
the thyroid-pituitary homeostatic mechanism and per-
formed a mathematical analysis of the model structures.
Notable from our perspective is the work by Mak et al. [19]
who developed a model for hypothyroidism consisting of 6
compartments describing T3 and T4 concentration in
plasma, extravascular tissue and general tissue, and 17
model parameters. Other models taking complex details
into account to characterize interactions in the HPT axis
were developed by Leow [32], Degon et al. [33], or
Eisenberg et al. [21]. Mukhopadhya et al. [34] and Ber-
berich et al. [35] even applied delay differential equations
[36] to capture existing time delays in the interactions.
Remarkable is the systems pharmacology model by Ekerot
et al. [22] based on pharmacokinetic/pharmacodynamic
concepts to describe the impact of thyroperoxidase inhi-
bition in dogs where model parameters are estimated with
non-linear mixed-effects modeling. On one hand, all of
these models offer great insights into the detailed mecha-
nism of the HPT axis but they are on the other hand dif-
ficult to apply to clinical data due to their complexity.
Development of an applicable and predictive mathematical
model for clinical practice is a tradeoff between available
data, prior knowledge from literature, complexity of the
underlying physiological and pathophysiological mecha-
nisms, and, most importantly, the capability to address
clinically relevant research questions. The final structure of
our developed PMX model for FT4 measurements and LT4
treatment was a one-compartment model with absorption
and an additional zero-order endogenous production rate.
The endogenous production rate of T4 allows testing for
TSH feedback effects. More precisely, low FT4 levels
cause increased TSH levels which in turn should stimulate
FT4 production. TSH is a highly variable biomarker for
thyroid functionality. However, it is unclear how strong the
TSH feedback effect is on the FT4 production in CH
patients. We tested different mathematical terms to esti-
mate the effect of TSH concentration on the endogenous
production rate of T4 but could not identify a significant
effect based on (i) estimated model parameters, (ii)
reduction of objective function value, and (iii) diagnostic
plots. The following three reasons may explain these
unexpected results. First, the cause of the disease is unre-
sponsiveness or reduced responsiveness of the thyroid
gland to produce FT4 to even high levels of TSH as seen at
the FT4 and TSH values at diagnosis. Thus, the expected
stimulatory effect of TSH is not or clearly less efficient in
patients with CH than in healthy individuals. Second, only
52 of 505 measurements represent pairs of TSH and FT4
before start of LT4 treatment and an effect would only be
found gradually in the moderate to mild forms further
reducing the numbers. Third, after initiation of substitutive
treatment with LT4, TSH is falling back into the target
reference range as the result of a normally functioning
negative feedback loop to exogenously administered LT4
on TSH synthesis and secretion. Further, TSH remains in
the target reference range during long-term treatment, if the
dose is ideally adapted to the needs of the growing child.
Lack of modeling a feedback from TSH on FT4 should not
be overestimated since it makes the developed PMX model
even more applicable to the clinical setting, where TSH
measurements might be missing.
In summary, this research article discussed challenges in
analyzing retrospective data from pediatric patients with a
rare disease and presented a practical and clinically useful
PMX model that characterizes FT4 concentration under
LT4 treatment in newborns and infants with CH.
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